PhRMA’s Post

PBMs and health insurers decide what medicines you can get, and they set the price you pay at the pharmacy. At the same time, over half of every dollar spent on medicines goes to these middlemen and others. Find out more: https://lnkd.in/e2eY5jCz

The U.S. biopharmaceutical industry leads the world in developing innovative vaccine technology. Each vial at the pharmacy and doctor’s office represents years of R&D by biopharmaceutical researchers.  ⬇️ Download our new report to learn how our leadership in vaccine research ensures advancements can continue. https://lnkd.in/e9WRzBJw

The process of bringing a new medicine to market is lengthy, expensive and incredibly uncertain. Intellectual property protections help incentivize this investment and research, bringing new, valuable medicines to patients. See how: https://lnkd.in/eH2NeTP5

A new FTC interim report underscores how pharmacy benefit managers (PBMs) profit at patients’ expense and drive up medicine costs.    The report details how PBMs: ➡️ steer patients to pharmacies they own ➡️ control what medicines are covered and what patients pay for them ➡️ reduce competition and push out independent pharmacies ➡️ pocket rebates meant for patients  

Americans are calling on policymakers to address harmful practices by insurers and pharmacy benefit managers (PBMs) that limit access to new medicines and treatments. A recent Morning Consult/PhRMA poll of over 20,000 Americans across all 50 states and 435 congressional districts reveals that 8 in 10 Americans are concerned that: - PBMs profit off of financial assistance that is intended to help patients afford the medicine they need, or block people from using this assistance altogether. - PBMs influence what medicines patients get and control what patients pay at the pharmacy. It's clear Americans want real solutions that hold big insurers and their PBM middlemen accountable for making it harder for patients to get the care they need. Dive into the poll's key findings below.

Treatments for Alzheimer’s can mean more to patients and caregivers than just slowing down the disease. They can mean more time to do things on their own and more conversations with friends, kids and grandkids. Chris Leibman, SVP, Value, Access, Public Policy and Government Affairs at Biogen, shares the value of these therapies with our COO Lori Reilly: https://lnkd.in/eyTEu8rD

The IRA’s price setting provisions could result in 3.5 million Medicare patients facing higher out-of-pocket costs in 2026 – undermining the benefits of the new out-of-pocket limit for millions of seniors and people with disabilities. More: https://lnkd.in/dvF2qJdM

Alzheimer’s disease is a devastating illness that gradually robs a person of everything they hold dear. Recently, Lori Reilly spoke with Shobha Dhadda of Eisai US about the life-changing impact new treatments could have on patients and caregivers. Watch the full conversation: https://lnkd.in/eZ-Gcx5X

"They are called pharmacy benefit managers. And they are driving up drug costs for millions of people, employers and the government."    Below, The New York Times exposes the abusive tactics of PBMs, reporting on how they control patients’ access to meds, pocket patient savings, and drive up costs.